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Abstract
Background: Epithelial-to-mesenchymal transition (EMT) is associated with downregulated E-cadherin and frequently
with decreased proliferation. Proliferation may be restored in secondary metastases by mesenchymal-to-epithelial
transition (MET). We tested whether E-cadherin maintains epithelial proliferation in MDA-MB-468 breast cancer cells,
facilitating metastatic colonization in severe combined immunodeficiency (SCID) mice.
Methods: EMT/MET markers were assessed in xenograft tumors by immunohistochemistry. Stable E-cadherin
manipulation was effected by transfection and verified by Western blotting, immunocytochemistry, and quantitative
polymerase chain reaction (qPCR). Effects of E-cadherin manipulation on proliferation and chemomigration were
assessed in vitro by performing sulforhodamine B assays and Transwell assays, respectively. Invasion was assessed by
Matrigel outgrowth; growth in vivo was assessed in SCID mice; and EMT status was assessed by qPCR. Hypoxic
response of E-cadherin knockdown cell lines was assessed by qPCR after hypoxic culture. Repeated measures
analysis of variance (ANOVA), one- and two-way ANOVA with posttests, and paired Student’s t tests were performed
to determine significance (p < 0.05).
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Results: EMT occurred at the necrotic interface of MDA-MB-468 xenografts in regions of hypoxia. Extratumoral deposits
(vascular and lymphatic inclusions, local and axillary nodes, and lung metastases) strongly expressed E-cadherin. MDA-
MB-468 cells overexpressing E-cadherin were more proliferative and less migratory in vitro, whereas E-cadherin
knockdown (short hairpin CDH1 [shCDH1]) cells were more migratory and invasive, less proliferative, and took
longer to form tumors. shCDH1-MDA-MB-468 xenografts did not contain the hypoxia-induced necrotic areas observed
in wild-type (WT) and shSCR-MDA-MB-468 tumors, but they did not exhibit an impaired hypoxic response in vitro.
Although vimentin expression was not stimulated by E-cadherin knockdown in 2D or 3D cultures, xenografts of these
cells were globally vimentin-positive rather than exhibiting regional EMT, and they expressed higher SNA1 than their in
vitro counterparts. E-cadherin suppression caused a trend toward reduced lung metastasis, whereas E-cadherin
overexpression resulted in the reverse trend, consistent with the increased proliferation rate and predominantly
epithelial phenotype of MDA-MB-468 cells outside the primary xenograft. This was also originally observed in WT
xenografts. Furthermore, we found that patients with breast cancer that expressed E-cadherin were more likely to
have metastases.
Conclusions: E-cadherin expression promotes growth of primary breast tumors and conceivably the formation of
metastases, supporting a role for MET in metastasis. E-cadherin needs to be reevaluated as a tumor suppressor.
Keywords: Breast cancer, E-cadherin, Epithelial-to-mesenchymal transition, Epithelial-mesenchymal plasticity,
Proliferation, Metastasis
Background
In 2016 alone, 3073 people died as a result of breast can-
cer in Australia [1], with essentially all breast cancer
deaths being due to metastasis [2, 3]. Accumulating
evidence suggests that epithelial-mesenchymal plasticity
(EMP), which is critical for the formation of new tissues
during embryonic development, also facilitates metastasis
from carcinomas, including breast cancer [4, 5]. In parallel
to its role in normal mammary gland development [6–11],
EMP in the mesenchymal direction (epithelial-to-mesen-
chymal transition [EMT]) is responsible for converting a
fraction of noninvasive tumor cells from a carcinoma into
stemlike cells with the ability to resist therapies, migrate,
invade, intravasate, and survive in the systemic circulation
[12, 13]. The reverse, mesenchymal-to-epithelial transition
(MET), is thought to allow cells the cohesiveness to
colonize new sites (reviewed in [4, 14–18]).
E-cadherin is a Ca2+-dependent transmembrane glyco-
protein present in the epithelial cell membrane, maintain-
ing intercellular adhesion through the formation of
adherens junctions [19, 20]. E-cadherin plays a pivotal role
in embryonic morphogenesis, mainly through governing
early cellular differentiation pathways [21, 22]. Functional
loss or downregulation of E-cadherin from epithelial cells
is considered a hallmark of EMT [23, 24]. The first tran-
scriptional suppressor of E-cadherin and inducer of EMT
to be identified was the zinc finger transcription factor
Snail family transcriptional repressor 1 (SNAI1) [24, 25].
Since then, other E-cadherin suppressors and EMT in-
ducers, such as Snail family transcriptional repressor 2
(SNAI2, Slug), zinc finger E-box-binding homeobox 1
(ZEB1)/TCF8, ZEB2 (SIP-1), Goosecoid, Twist-1, and
Forkhead box protein C2 (FOXC2), have emerged [26–
32]. All of these transcription regulators downregulate E-
cadherin expression, potentially inducing EMT [33]. Given
the striking similarities between cell translocation dur-
ing embryonic morphogenesis and cancer metastasis
[34, 35], E-cadherin has emerged as an important can-
didate regulator of the metastatic process in cancers of
epithelial origin [36, 37].
Although EMT is a major mechanism contributing to
tumor progression, unchecked cellular proliferation is
the driver of tumor growth. Accumulating evidence sug-
gests that EMT and cellular proliferation are inversely
associated and that EMT attenuates cell proliferation in
some [38, 39] but not all [40, 41] systems. Researchers in
an early study on well-differentiated colorectal adenocar-
cinomas with lymph node (LN) metastasis reported loss
of the proliferative marker Ki-67 in the cells along the
invasive front in de-differentiated primary and secondary
tumors, in contrast to the presence of high Ki-67 at the
tumor center [42]. They observed diminished membran-
ous E-cadherin and nuclear localized β-catenin in the
Ki-67-negative cells at the invasive front, indicating at-
tenuated proliferation in cells that have undergone
EMT. This is reflected by the more recent finding that
breast cancer stem cells located at the invasive front are
primarily quiescent, whereas those in a more central lo-
cation within the tumor are proliferative and retain the
ability to transition between these states [43]. In turn,
the antiproliferative drug cisplatin has been shown to in-
duce EMT [44]. We have shown in breast cancer cells
that suppression of proliferation by EMT is mediated at
least in part through ZEB1 repression of MYB, a gene
important in driving proliferation of estrogen receptor
(ER)-positive primary breast cancers [38].
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MET is also critical in the developmental formation of
new tissues as occurs in nephrogenesis [45], and it fuels
the formation of metastatic tumors at the secondary site
[4, 14, 18, 46–50]. Chao et al. [46] reported reexpression
of E-cadherin in distant metastases arising in organs
such as the liver, brain, and lung from primary breast tu-
mors that were E-cadherin-low or E-cadherin-negative,
and they suggested that the reexpression of E-cadherin
in metastases was mediated by E-cadherin promoter de-
methylation influenced by the microenvironment of the
metastatic site. Several other studies support the reexpres-
sion of E-cadherin at secondary sites [51–53]. This reex-
pression may reactivate cellular proliferation within the
cells that emerge from the circulation at the secondary
site, allowing them to form bulky metastases within the
targeted niche organ, as reviewed elsewhere [14, 54, 55].
Although xenografts of MDA-MB-468 human breast
cancer cells have been well described [56–58], relatively
few studies have explored metastasis and EMP [59–61].
In the present study, we examined further the relation-
ships between EMP status, proliferation, and metastasis
through manipulation of E-cadherin in these cells.
Methods
Cell line and culture conditions
The MDA-MB-468 breast cancer cell line used in this
study was originally obtained from the American Type Cul-
ture Collection (Manassas, VA, USA) by the Georgetown
Lombardi Comprehensive Cancer Center (Washington,
DC, USA) [62]. Cell cultures were routinely maintained in
DMEM (Sigma-Aldrich, St. Louis, MO, USA) containing
glucose (4500 mg/L), L-glutamine, and sodium pyruvate
(110 mg/L) and supplemented with 10% FBS (SAFC Bio-
sciences, Castle Hill, Australia). Cultures were maintained
in antibiotic-free growth medium at 37 °C in a humidified
incubator with O2 and CO2 levels set at 21% and 5%, re-
spectively. For induction of hypoxia (HPX) in culture, the
cells were passaged in DMEM supplemented with 10%
FBS and incubated at 37 °C on an InvivO2 400 worksta-
tion (Ruskinn Technology Ltd, Bridgend, UK) at 1% O2
and 5% CO2, and the cells were harvested at 48 h.
Immunocytochemistry
MDA-MB-468 cells were plated in 96-well Terasaki
plates (NuncTM; Thermo Fisher Scientific, Roskilde,
Denmark), and immunofluorescence was performed as
previously described [38]. A volume of 12 μl per Tera-
saki well was used.
Immunohistochemistry
Formalin-fixed, paraffin-embedded tissues were sectioned
onto microscopic slides (SuperFrost® Plus; Menzel-Gläser,
Braunschweig, Germany). Slides were then incubated in a
humidified chamber with the primary antibody (antibodies
used are listed in Table 2) and diluted in blocking buffer
(PBS with 0.1% bovine serum albumin [BSA]) for 1 h at
room temperature or at 4 °C overnight. The slides were
next incubated with a biotinylated secondary antibody
(raised against the immunoglobulin G [IgG] of the pri-
mary IgG species) for 1 h at room temperature, then incu-
bated with HRP-conjugated streptavidin-biotin complex
(Dako, Glostrup, Denmark) for 1 h at room temperature
and stained with freshly prepared 3,3′-diaminobenzidine
(DAB; Sigma-Aldrich). Slides were counterstained with
hematoxylin for 5 minutes, mounted in dibutylphthalate
polystyrene xylene (DPX), and coverslipped. The double
immunohistochemistry (IHC) was performed using the
BenchMark® ULTRA automated slide stainer (Ventana
Medical Systems, Inc., Tucson, AZ, USA) in the Depart-
ment of Pathology, St. Vincent’s Hospital, Melbourne,
Australia. The chromogens used were ultraView® Univer-
sal Alkaline Phosphatase Fast Red (red color, vimentin)
and ultraView® Universal DAB (brown color, E-cadherin)
(both from Ventana Medical Systems, Inc.).
Obtaining red-channel images
The color deconvolution plugin in ImageJ software (ver-
sion 1.51j8; public domain program created by Wayne
Rasband, National Institutes of Health, Bethesda, MD,
USA) was used, set for Fast Red DAB, to obtain the red
channel images in the E-cadherin/vimentin dual-stained
images.
Sulforhodamine B cell proliferation assay
The sulforhodamine B (SRB) colorimetric assay (Sigma-
Aldrich) measures the amount of protein content, which
is proportional to the number of cells [63]. The assays
were performed in 96-well tissue culture plates contain-
ing 0.1 ml of culture medium per well and between 2500
and 20,000 cells per well. A series of plates were pre-
pared with a desired number of cells per well and incu-
bated at 37 °C in an incubator with O2 and CO2 set at
21% and 0.5%, respectively. The day of cell seeding was
considered as day −2. One day after cell seeding (day
−1), the normal culture medium was replaced with
serum-free medium, followed by incubation for 24 h.
Plates were fixed in 50% trichloroacetic acid (TCA), then
25 μl of prechilled (4 °C) 50% TCA was gently added to
the growth medium in each well to give a final concen-
tration of 10% TCA. The plates were then incubated at
4 °C for 1 h, followed by gentle washing with tap water.
Washes were repeated five times for complete removal
of TCA and growth medium and then air-dried over-
night and stored at room temperature. At the end of the
experiment, once all the plates had been TCA-fixed and
air-dried, they were collectively stained for 30 minutes
by adding 100 μl of freshly prepared 0.4% SRB (wt/vol)
in 1% acetic acid per well. The plates were then washed
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five times with 1% acetic acid to completely remove
protein-unbound stain. Plates were air-dried overnight at
room temperature. SRB dye-bound protein appears bright
pink in color. This was solubilized by adding 100 μl of
10 mM Tris base (pH 10.5) and incubating for 20–30 mi-
nutes on a gyratory shaker at room temperature. The op-
tical density (OD) of absorbance at 540-nm wavelength
was then measured in a microplate reader (POLARstar
OPTIMA; BMG LABTECH, Ortenberg, Germany). The
average of the OD values measured in the PBS-containing
outer wells, which was generally about 0.04, was consid-
ered as the background OD. The results were analyzed
using Prism version 5 software (GraphPad Software, La
Jolla, CA, USA).
Creation of modified cell lines
E-cadherin was exogenously expressed in MDA-MB-468
cells, referred to as 468-CDH1, by transfecting the cells
with the plasmid hECD-pcDNA3 [64] using Lipofectami-
neTM 2000 reagent (Invitrogen, Carlsbad, CA, USA) ac-
cording to the manufacturer’s instructions. The cells were
maintained in 600 μg/ml of G418 (geneticin; Invitrogen)
in growth medium for 6–8 weeks to establish a stable,
pooled cell line. Short hairpin RNA (shRNA)-expressing
MDA-MB-468 cell pools, referred to as 468-shCDH1-A,
-B, -C, or -D, were generated using the Lenti-X HTX
packaging system (Clontech Laboratories, Mountain View,
CA, USA). shRNA sequences (Table 1), along with a non-
silencing shRNA microRNA (miR) lentiviral control vec-
tor containing a scrambled sequence with no homology to
any known mammalian genes (Open Biosystems, Lafa-
yette, CO, USA), were encoded within a green fluorescent
protein (GFP)-expressing lentiviral vector (pGIPZ; Open
Biosystems). Successfully transduced cells were selected
by cell sorting for GFP; thus, a transduced pool rather
than individual clones was used in these studies.
Western blotting and quantitative real-time polymerase
chain reaction experiments
These techniques were performed as previously described
[38] to determine the degree of E-cadherin overexpression,
depletion, or knockdown in the various modified cell lines.
Antibodies used are detailed in Table 2. Quantitative real-
time polymerase chain reaction (RT-qPCR) experiments
were performed using gene-specific primers designed spe-
cially to detect either the exogenously expressed E-
cadherin or the targeted sequences in shRNA-infected
cells. Primer sequences are detailed in Table 3.
Transwell chemotaxis migration assay
The Transwell migration assay was performed using 24-
well Transwell® permeable inserts containing polycar-
bonate membranes with 6.5-mm diameter, 8-μm pore
size, and 0.3-cm3 bottom area (catalogue number 3422;
Corning Life Sciences, Corning, NY, USA). MDA-MB-
468 cells were resuspended at 1 × 106 live cells/ml in
FBS-free DMEM supplemented with 0.1% BSA. While
the cell suspensions were prepared, 600 μl of the chemo-
attractant (DMEM supplemented with 10% FBS and
0.1% BSA) was dispensed into each well of the 24-well
Transwell plates and warmed to 37 °C. The Transwell
inserts were placed in the bottom wells containing pre-
warmed chemoattractant, and 1 × 105 cells (100 μl from
the cell suspension) were applied to each well. The
Transwell plates were then incubated at 37 °C for 4.5 h,
after which the growth medium in the inserts was re-
moved and the membranes were washed twice in PBS.
The membranes were then fixed in methanol for 1 mi-
nute and stained with Diff-Quik (Siemens, Bayswater,
Australia) for 1 minute with eosin followed by 1 minute
with buffered thiazole and washed with several changes
of water to completely remove excess stain. The nonmi-
grated cells on the top side of the membranes were gen-
tly wiped off using wet cotton swabs. The membranes
were left to air-dry overnight, carefully peeled off from
the inserts, and placed onto microscopic slides with the
migrated cells facing down, mounted in DPX mounting
medium, and coverslipped. The number of migrated
cells in five random high-power fields per membrane
was counted using ImageJ software.
Matrigel outgrowth assay (nubbin assay)
The Matrigel outgrowth assay was performed as described
by Price and Thompson [65] using a 96-well plate setup.
The desired number of cells (titration was done using 250,
500, and 1000 cells per well) were mixed in 5 μl of Matri-
gel and transferred into each well. The cell and Matrigel
mixture was allowed to set by incubating at 37 °C for
15 minutes. Once the gel was set, 80 μl of DMEM supple-
mented with 10% FBS was carefully added to each well.
The assay was then incubated at 37 °C for 1 week. The
wells were photographed daily, and the morphological
changes seen in the cells were assessed and recoded.
Inoculation of severe combined immunodeficiency mice
with E-cadherin-modified cell lines
MDA-MB-468 cells were grown in T175 flasks (Thermo
Fisher Scientific, Australia) to approximately 70% conflu-
ence. Cells were trypsinized to a single-cell suspension,
washed three times in PBS, and resuspended to 1.33 × 108
Table 1 Short hairpin RNA used in this study
Cell line Clone ID Sequence
468-shCDH1-A V2LHS_14834 CTGTTGGTGTCTTTATTAT
468-shCDH1-B V2LHS_14838 GTCGTAATCACCACACTGA
468-shCDH1-C V2LHS_14837 CCAACTGGCTGGAGATTAA
468-shCDH1-D V2LHS_ 243170 GAGAGAGTTTCCCTACGTA
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viable cells in 1 ml of PBS. The cell suspension was kept
on ice until used for inoculation. All of the experimental
procedures pertaining to this section were performed ac-
cording to the guidelines stipulated by the animal ethics
committee (AEC) at St. Vincent’s Hospital, Melbourne
(AEC protocol number 008/08). Severe combined im-
munodeficiency (SCID) mice (8–10 weeks old) were ob-
tained from the animal resource center in Perth, Australia.
Briefly, the mice were anesthetized with isoflurane, the
lower abdominal region of the mouse was cleaned with
70% ethanol, and a vertical paramedial skin incision of
about 1 cm was made in the lower right abdominal region
overlying the mammary fat pad (MFP). The cell suspen-
sion (15 μl containing 2 × 106 MDA-MB-468 cells) was
injected into the MFP using a 50-μl Hamilton syringe.
After inoculation of the cells, the incision was closed with
two stainless steel wound clips, which were removed once
the incision wounds were completely healed. The mice
were monitored twice weekly throughout the experiment,
and tumor dimensions and body weights were recorded.
The volume of the tumor was estimated as width of the
tumor squared multiplied by (length of the tumor divided
by 2) and expressed in cubic millimeters. Mice were killed
when the tumor volume reached 10% of the body weight.
Tissues were harvested after mice were killed by exposing
them to a high dose of CO2. The xenograft tumors were re-
moved carefully, weighed, and photographed. One-half of
the tumor was then fixed in formalin for histological ana-
lysis and IHC. The other half was chopped into small pieces
and rapidly frozen in liquid nitrogen for RNA analysis. The
lungs were fixed in formalin for histological analysis.
Determining tumor/necrosis ratio
The tumor/necrosis ratio was assessed among the tumor
groups by scanning the hematoxylin and eosin (H&E)-
stained slides using Aperio ScanScope® slide scanner
(Leica Biosystems, Buffalo Grove, IL, USA). The propor-
tion of area representing viable tumor tissue and necro-
sis was then estimated with JMicroVision software.
Analysis of human clinical data
All analyses of public and shared E-cadherin datasets
were performed using the University of California Santa
Cruz Xena program (http://xena.ucsc.edu/).
Statistical analyses
Repeated measures analysis of variance (ANOVA) and
two-way ANOVA with Bonferroni’s multiple compari-
sons posttest or Dunnett’s multiple comparisons post-
test, one-way ANOVA, Student’s paired t tests, log-rank
(Mantel-Cox) statistical tests, and Welch’s t tests were
performed using Prism software. Where “n” is used (as
in n = 3), this refers to the number of independent, bio-
logic replicate experiments performed.
Results
MDA-MB-468 tumors exhibit regions of EMP associated
with hypoxia
Consistent with previous results [66], the differential
EMP status in these xenograft tumors was demonstrable
by double IHC of E-cadherin (Fig. 1a, brown) and
vimentin (Fig. 1a, red). Vimentin-positive cells (red
color) indicating EMT were clearly seen in two distinct
Table 2 Antibodies used in this study
Species Source Catalogue number
Primary antibody
Human E-cadherin Rabbit Abcam, Cambridge, UK Ab15148
Human E-cadherin Mouse BD Biosciences, San Jose, CA, USA 610404
Human vimentin Mouse Dako, Glostrup, Denmark M0725
α-Pan-actin Mouse Abcam, Cambridge, UK Ab14128
Human mitochondrial Mouse Thermo Fisher Scientific, Waltham, MA, USA MA5-12017
Mouse CD31 Rat BD Pharmingen, San Diego, CA, USA 550274
Human HIF-1α Mouse BD Biosciences, San Jose, CA, USA 610958
Secondary antibody
Antimouse biotin Rabbit Dako, Campbellfield, Australia E0354
Antirabbit biotin Swine Dako, Campbellfield, Australia E0431
Antirat biotin Goat Vector Laboratories, Burlingame, CA, USA BA-9401
Antirabbit Alexa Fluor® 594 Donkey Molecular Probes, Eugene, OR, USA R37119
Antimouse Alexa Fluor® 488 Goat Molecular Probes, Eugene, OR, USA A11001
Tertiary label
Streptavidin/HRP Dako, Campbellfield, Australia P0397
HIF Hypoxia-inducible factor
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areas of the tumor: at regions of the tumor-stroma inter-
face (blue arrows) and along the tumor-necrosis border
(yellow arrows). Cells between these two layers were
mainly vimentin-negative and E-cadherin-positive (brown
color). Some of the vimentin-positive cells in the tumor-
stroma interface were also positive for E-cadherin, indicat-
ing a hybrid phenotype. The vimentin-positive cells at the
invasion front were arranged in thin rows of individual
cells interspersed between stromal (S) connective tissue
(blue arrow), typical of the invasive lobular carcinoma that
lacks E-cadherin [67]. Vimentin-positive cells along
the necrosis (N) front were also arranged in a thin
border (yellow arrow). Human skin was used as the
positive control for both E-cadherin and vimentin
staining (Fig. 1a).
We hypothesized that the EMP seen along the tumor-
necrosis border could be a consequence of HPX, given re-
cent reports of HPX-induced EMT in MDA-MB-468 cells
[68, 69] in addition to our own in vitro study [70]. To as-
sess HPX in the xenograft tumors, IHC staining of the
HPX marker hypoxia-inducible factor-1α (HIF-1α) was
performed. HIF-1α-positive cells (black arrow) were dis-
tributed along the tumor (T)-necrosis (N) border only,
corresponding to the region containing the vimentin-
positive cells (Fig. 1b, black arrow), as also seen in islands
of tissue surrounding vessels within the necrotic region
(Additional file 1: Figure S1a). These combined results as-
sociate the necrotic interface EMT with HPX and suggest
an HPX-independent EMT induction mechanism indu-
cing vimentin at the tumor-stroma border.
Table 3 Primers used in this study
Primer name Nucleotide sequence
L32 RT sequence CAGAAAACGTGCACATGAGCTGC
Forward sequence (outer nested) CAGGGTTCGTAGAAGATTCAAGGG
Reverse sequence (outer nested) CTTGGAGGAAACATTGTGAGCGATC
Forward sequence (inner nested) GATCTTGATGCCCAACATTGGTTATG
Reverse sequence (inner nested) GCACTTCCAGCTCCTTGACG
Carbonic Anhydrase 9 (for hypoxia validation) Random priming used
Forward CCTCAAGAACCCCAGAATAATGC
Reverse CCTCCATAGCGCCAATGACT
E-cadherin RT sequence GTCAGCCAGCTTCTTGAAGCGATT
Forward sequence GCCCTGCCAATCCCGATGAAA
Reverse sequence GGGGTCAGTATCAGCCGCT
Vimentin RT sequence CCGTGAGGTCAGGCTTGGAAA
Forward sequence GCTTCAGAGAGAGGAAGCCGAAAA
Reverse sequence CCGTGAGGTCAGGCTTGGAAA
Endogenous E-cadherin (CDH1-3′UTR) RT sequence GCACTTGGGGATTCTGGGCTTT
Forward sequence GTGCCTAAAGTGCTGCAGCCAAA
Reverse sequence GTACAAACCACGGATCTTGTGTCAGAAA
Exogenous E-cadherin (for 468-CDH1 construct) RT sequence GAAAGGACAGTGGGAGTGGCACTTT
Forward sequence CCTGAACTCCTCAGAGTCAGACAAA
Reverse sequence GTGGCACCTTCCAGGGTCAAGGAA
E-cadherin shRNA (for 468-shCDH1 constructs) RT sequence CCAGCTCAGCCCGAGTGGAAAT
Forward sequence CCTCCCATCAGCTGCCCAGAAAA
Reverse sequence CTCTGTCACCTTCAGCCATCCTGTTT
Snail 1 RT sequence CGCAGACAGGCCAGCTCAGGAAT
Forward sequence CACATCCTTCTCACTGCCATGGAATT
Reverse sequence GCTGCCCTCCCTCCACAGAAAT
Estrogen Receptor 1 RT sequence CCAGGGCCACGCTGGGAAATGAA
Forward sequence GTTCCAGTGGGCACTGTACTTGGATCTT
Reverse sequence CAGCTCCATGCCCCAGGGCTAAAT
Abbreviations: RT reverse transcription, shRNA Short hairpin RNA
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Metastases of MDA-MB-468 xenograft primary tumors
exhibit evidence of epithelial differentiation, consistent
with MET
An interesting histological feature observed in the
MDA-MB-468 tumors was the existence of carcinoma in
situ-like areas (Fig. 2a). These spherical tumor masses
were surrounded by connective tissue fibers, presenting
as encapsulated tumor. They were generally located to-
ward the periphery of the tumors and were composed of
cohesive tumor cells that strongly expressed E-cadherin,
in contrast to the neighboring vimentin-positive cells at
the invasive front of the tumor. As shown in Fig. 2a(i)
and (ii), the pattern of Ki-67 staining in the MDA-MB-
468 tumors did not correlate with either vimentin or E-
a
b
Fig. 1 a Epithelial-to-mesenchymal transition (EMT) in MDA-MB-468 xenograft tumors. Vimentin-positive cells (red) indicating EMT were seen in
regions along the tumor-stroma interface (blue arrows) and more continuously along the tumor-necrosis border (yellow arrows). The vimentin-
positive cells at the invasion front were arranged in thin rows of individual cells interspersed between stromal (S) connective tissue (blue arrows).
Vimentin-positive cells along the necrosis (N) front were also arranged in a thin border (yellow arrows). A red-colored deconvoluted image is
shown to enable discernment of vimentin immunohistochemical staining. E-cadherin/vimentin-positive control: human skin. Scale bars represent
50 μm. b Evidence of epithelial-mesenchymal plasticity in MDA-MB-468 cell xenografts in regions associated with hypoxia. Images at right are
red-channel images (derived from image using the ImageJ Colour Deconvolution plugin) of images at left to more clearly illustrate features. Area
of necrosis is denoted with yellow N, tumor is denoted with black T. Hypoxia-inducible factor (HIF)-1α-positive cells were seen along the tumor-
necrosis border (black arrow), and the area was also positive for vimentin (scale bar = 50 μM). For another example, see Additional file 1: Figure S1
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cadherin staining in the tumor proper or in the zones of
EMT, and it was expressed in approximately 90% of all
cells in the growing tumor.
As shown in Fig. 2b, metastatic tumor cells were seen
in some LNs within close proximity of the lungs and
within the lungs themselves, with positive staining with
a human-specific mitochondrial antibody confirming
that these cell clusters were of human origin. Lung
micrometastases were seen across all the groups, with a
marked trend toward E-cadherin-expressing groups
(Table 4).
MDA-MB-468 tumor cells were detected in LNs asso-
ciated with the lungs and as micrometastases within the
lungs themselves (Fig. 2c). Confirmation of the presence
of cells of human origin was obtained by a human-
specific, antimitochondrial antibody (T) with mouse
a (i)
a (ii)
b
c
Fig. 2 Pronounced expression of E-cadherin was observed in MDA-MB-468 xenograft metastases. a (i) and (ii) Similarity of features of MDA-MB-
468 xenograft tumors. Red-channel image is shown for simplicity of vimentin staining. b Metastatic tumor cells in lymph nodes (LNs) and lungs.
Positive staining for an antihuman mitochondrial antibody confirmed that tumor cells were of human origin (T), whereas mouse lymphocytes (L)
were not stained. Tumor cells in the lung demonstrated E-cadherin expression but not vimentin. c LN invasion. Black arrows indicate invasion of
E-cadherin and vimentin-expressing tumor cells to the adjacent LNs (T). Red-channel image is shown for clarity of vimentin staining. Tumor cells
in axillary nodes stained homogeneously for E-cadherin. Lymphoid tissue (L) did not stain for either E-cadherin or vimentin, confirming its murine
origin. All scale bars = 50 μm, except for axillary LN images, where scale bar represents 100 μm. H&E Hematoxylin and eosin
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unstained (L) (Fig. 2c, inset). Most of the cells demon-
strated E-cadherin expression; however, none were posi-
tive for vimentin, indicating an epithelial phenotype.
Both local and distant LN (axillary) metastases were ob-
served in a subset of mice (n = 4) with MDA-MB-468
xenograft tumors (Fig. 2c). The tumor cells that invaded
into the local LNs generally displayed a heterogeneous
expression pattern of E-cadherin and vimentin, as shown
in the enlarged image, an indication that these cells dis-
played a spectrum of EMP, although epithelial cells with
strong E-cadherin expression were the most abundant.
In contrast, tumor cells in the axillary nodes stained
homogeneously for E-cadherin. These results support a
requirement for epithelial phenotype for secondary
colonization by metastasized tumor cells and support
the possibility of MET.
Creation and validation of E-cadherin-modified MDA-MB-
468 cell lines
Given that EMP was observable in MDA-MB-468 cells
grown in vivo in xenografts (Fig. 1) and that E-cadherin
was a strong feature of secondary deposits (Fig. 2), we
sought to enforce either stable epithelial or mesenchy-
mal status in the MDA-MB-468 cell system by directly
manipulating E-cadherin expression positively or nega-
tively, respectively, and to examine MDA-MB-468 cell
behavior in vivo. Manipulation of E-cadherin has been
used effectively for EMP studies in HMLE human epi-
thelial mammary cells [71], human head and neck squa-
mous carcinoma cells [72], and dog kidney and mouse
mammary carcinoma cells [73].
MDA-MB-468 cells were transfected with either full-
length human E-cadherin (468-CDH1) or four shRNA
variants (468-shCDH1-A–468-shCDH1-D) and a “scram-
bled” nontargeting hairpin control (468-shSCR) against
CDH1, as described in the “Methods” section above. Each
transfectant/transductant was characterized by Western
blotting and qPCR (Fig. 3a and b).
Western blotting (Fig. 3a, i) confirmed an elevated E-
cadherin protein level in 468-CDH1 cells compared with
468-pcDNA3 cells. Gene-specific qPCR analysis (Fig. 3a,
ii) was performed using primers designed to detect en-
dogenous versus exogenous forms of E-cadherin (see
Table 3 for primer sequences). The collective expression
of both exogenous and endogenous E-cadherin was de-
tected using a more general primer set (i.e., “E-cad over-
all” as labeled in Fig. 3a, ii). The endogenous E-cadherin
messenger RNA (mRNA) was assessed using a primer
pair targeting the 3′ untranslated region of the CDH1
gene. Both the cell types examined in Fig. 3a(iii)
expressed endogenous E-cadherin; however, the 468-
CDH1 cells also expressed exogenous E-cadherin, which
contributed to the E-cadherin measured in the overall
primer set, confirming the successful transfection of full-
length E-cadherin into MDA-MB-468 cells. Approxi-
mately 130-fold induction (2−ΔΔCt) was observed in the
expression of overall E-cadherin message, which was sta-
tistically significant in 468-CDH1 cells compared with
468-pcDNA3 cells, with no significant change in en-
dogenous E-cadherin expression. Vimentin expression in
468-CDH1 cells remained unchanged from the basal
level, despite their forced epithelial status (Fig. 3a, ii).
Characterization of shRNA variants compared with the
scrambled control by Western blotting showed that the
468-shCDH1-B and 468-shCDH1-D cells expressed the
least E-cadherin protein, and the least was seen in 468-
shCDH1-C cells (Fig. 3b, i). A comparable pattern was
also seen by qPCR (Fig. 3b, ii). As shown in Fig. 3c, the
best E-cadherin knockdown confirmed by qPCR (468-
shCDH1-B) exhibited further upregulated vimentin ex-
pression and E-cadherin repression above that of the
SCR short hairpin control when the cell lines were
treated with epidermal growth factor (EGF) for 5 days.
The EMT-related genes serpin family E member 1 (SER-
PINE1) and FOSL1 selected for analysis were based upon
a previously published gene set consistently upregulated
in our hands in MDA-MB-468 cells that underwent
EMT after treatment with either EGF or HPX [70].
Snail1 was selected because it was shown to be upregu-
lated by EGF in this previous study. All EMT genes were
upregulated by EGF in all cell lines tested, except for
SERPINE1, which was downregulated in 468-shCDH1-B
cells. Immunofluorescence for vimentin at this 5-day
treatment time point (Fig. 3c, ii) reflected the induction
by EGF observed by qPCR.
Forced E-cadherin expression blocked cellular invasion,
whereas its knockdown stimulated invasion and reduced
proliferative growth
We examined the invasive potential and proliferative
rate of the various E-cadherin-modified cells in culture
(Fig. 4).
Each cell line was assessed in the Transwell chemomi-
gration assay. The number of migrated 468-CDH1 cells
was significantly lower than the control 468-pcDNA3
control cells, indicating that overexpression of E-
cadherin in MDA-MB-468 cells significantly reduced
Table 4 Incidence of lung metastases across the tumor groups
Group Number
observed
With lung
metastasis
Percentage of
metastasis
468-shSCR 10 7 70
468-shCDH1-B 10 3 30
468-shCDH1-D 10 5 50
468-pcDNA3 9 5 55.6
468-CDH1 10 7 70
Fisher’s exact test was used to determine statistical significance
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their potential to migrate as single cells (Fig. 4a, i).
Compared with the 468-shSCR cells, the number of mi-
grated 468-shCDH1-B cells was significantly higher
(Fig. 4a, ii). Similarly, a higher rate of cell migration
was apparent in 468-shCDH1-D compared with the
vector control, although this was not statistically sig-
nificant. The results highlight that the functional
knockdown of E-cadherin achieved by shRNA in MDA-
MB-468 cells led to an increase in migratory capacity.
Similarly, the 468-shCDH1-B and 468-shCDH1-D cells
were more invasive, as shown by greater Matrigel out-
growth (Fig. 4b). In this assay, cells were evenly dis-
persed in a nubbin of Matrigel that was formed on a
Matrigel-coated well in a 96-well setup, topped with
FBS-supplemented DMEM and incubated at 37 °C. By
the seventh day of the assay, a portion of 468-
a (i)
c (i)
(ii)
(ii)
(ii)
b (i)
Fig. 3 Validation and characterization of E-cadherin-manipulated MDA-MB-468 cell lines. E-cadherin-overexpressing (a) and short hairpin RNA
(shRNA)-transduced (b) MDA-MB-468 cells assessed by (i) Western blotting and (ii) quantitative polymerase chain reaction (qPCR) (error bars
represent SEM in three independent experiments). Statistical significance was determined by two-tailed, paired t test; *** p < 0.0001, ** p < 0.01
and * p < 0.05. c (i) Treatment of 468-shCDH1 cells with epidermal growth factor (EGF) to assess their ability to undergo epithelial-to-mesenchymal
transition (EMT) by qPCR for various EMT genes. Fold expression (from the control) is shown, where control = 1 and y-axis is on a logarithmic scale.
Error bars represent SEM derived from three independent experiments. (ii) Matching vimentin immunofluorescence (combined with nuclear
4′,6-diamidino-2-phenylindole [DAPI] stain) of the cells at day 5 time point (scale bar represents 50 μm). ΔCT Cycle threshold change, UTR
Untranslated region
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CDH1shRNA-B and 468-CDH1shRNA-D cells had in-
vaded through the 3D culture coating to the floor of
the well, where they displayed an elongated phenotype
resembling mesenchymal cells. The noninvaded cells
remained trapped in the Matrigel and formed a spher-
oidal cluster of cells similar to the cell clusters formed
by 468-SCRshRNA cells. These results show that
knockdown of E-cadherin in MDA-MB-468 cells en-
hanced their invasive potential.
The SRB assay was performed to compare the rates of
cell proliferation. To determine if density affected this,
the cells were seeded at two different cell densities (2500
and 5000 cells per well; see Fig. 4c, i and ii, respectively).
No significant difference was observed between 468-
a (i)
(ii)
b
c (i) (ii)
Fig. 4 a Transwell chemotaxis migration assay (n = 3). Error bars represent SEM, and statistical significance was determined by two-tailed paired
t test; ** p < 0.0025, * p < 0.01. Original magnification × 200, scale bar = 50 μm. Images shown are representative only of the quantification shown
on right; quantification was determined from the entire cell layer. b Matrigel outgrowth (nubbin) assay to assess invasive potential. c Sulforhodamine B
assay (n= 3). Error bars represent SEM, and statistical significance was determined by two-way analysis of variance with Bonferroni’s posttest; * p< 0.001.
(i) Low seeding density: 2500 cells/well; (ii) high seeding density: 5000 cells/well seeding density. ns Not statistically significant
Hugo et al. Breast Cancer Research  (2017) 19:86 Page 11 of 25
pcDNA3 and 468-CDH1 cell lines with respect to prolif-
erative rate (data not shown); however, 468-shCDH1-B
and 468-shCDH1-D cells proliferated at noticeably lower
rates than the 468-shSCR control when plated at low
density (Fig. 4c, i). At twice the seeding cell density, an
initial lag was observed in the proliferative rate of 468-
shCDH1-B and 468-shCDH1-D cells, which gradually
disappeared by the sixth day (eighth day after cell seed-
ing). The results reveal that E-cadherin silencing has an
inhibitory effect on cell proliferation, which was more
prominent under sparse culture conditions.
E-cadherin-manipulated tumors grew slower than their
respective controls
We tested the primary tumor growth and metastatic
competence of the E-cadherin-manipulated cell lines by
orthotopically inoculating them into the MFPs of SCID
mice and subsequently analyzing the primary xenograft
tumor growth and extent of lung metastases. Details of
the cell groups used in the in vivo experiments are listed
in Table 5. No significant difference was detected be-
tween the 468-shSCR and 468-pcDNA3 groups from
days 80 to 119 (data not shown). As shown in Fig. 5a(i),
the 468-CDH1 xenografts appeared larger than the 468-
pcDNA3 ones at all time points and were significantly
larger on day 107, as determined by two-way ANOVA
with Bonferroni’s posttest.
The rate of tumor growth was more markedly different
among the 468-shSCR, 468-shCDH1-B, and 468-
shCDH1-D groups (Fig. 5a, ii). Although no obvious
changes were observed between 468-shSCR and 468-
shCDH1-B at the earlier time points, the tumor volume
was significantly lower in 468-shCDH1-B than in the
vector control 468-shSCR from 97 days onward postin-
oculation. A similar trend was also detected between the
468-shSCR and 468-CDH1shRNA-D groups, although
the difference in tumor growth was not seen until
105 days postinoculation. No difference was seen between
468-shCDH1-B and 468-shCDH1-D for up to 136 days
postinoculation, after which 468-shCDH1-D tumors dem-
onstrated a significantly higher tumor growth rate than
468-shCDH1-B (Fig. 5a, ii; Additional file 2: Figure S2a).
The results revealed that the tumor growth rate in E-
cadherin-knockdown groups was significantly slower than
their vector control, and this appeared to be dose-
dependent because 468-shCDH1-B had a more complete
knockdown than 468-shCDH1-D. Despite these marked
changes in tumor growth, no difference was observed in
Ki-67 staining in tumors from the E-cadherin-modified
cell lines (Additional file 3: Figure S3).
E-cadherin-knockdown tumors are less necrotic
Standard histopathological assessment of the xenografts
was performed by H&E staining. The tumors from all
groups except 468-shCDH1-B were composed of a central
necrotic area surrounded by a thin rim of viable tumor tis-
sue (Fig. 5b, i). A common feature detected in these tu-
mors was the presence of small islands of viable cells
surrounding a central blood vessel, embedded within the
central necrotic region. Tumors from the 468-shCDH1-B
group, regardless of tumor size, were composed mainly of
viable tumor tissue with only very small areas of necrotic
foci (Fig. 5b, i). The percentage of necrosis exceeded that
of viable tumor tissue across all groups except 468-
shCDH1-B, where the amount of viable tumor tissue was
considerably higher than the extent of necrosis (Fig. 5b,
ii). The proportion of viable tumor tissue was significantly
higher in 468-shCDH1-B tumors than in any other group.
Tumor microvasculature is more developed in 468-
shCDH1-B xenografts
We investigated whether differences in necrotic area be-
tween the various tumor types (Fig. 5b) was due to altered
vasculature using IHC staining of the vascular endothelial
marker CD31/platelet endothelial cell adhesion molecule-
1 (Fig. 6a, left panel). In 468-shCDH1-B tumors, the ma-
jority of blood vessels were larger with well-organized
architecture, as compared with the less substantial micro-
vasculature observed in the tumors across all other
groups, whereas no statistically significant change was de-
tected in the number of blood vessels across the tumor
groups (Fig. 6b). All tumor groups except 468-shCDH1-B
displayed positive HIF-1α staining (Fig. 6a, right panel),
consistent with HPX occurring within these tumors.
Where seen, these hypoxic regions correlated with vimen-
tin positivity (data not shown), as was originally observed
for WT MDA-MB-468 tumors (Fig. 1a).
E-cadherin knockdown in human breast cancer cell
line xenografts has been shown to decrease tumor
growth due to impaired HIF-1α expression and subse-
quent ability to metabolize glycogen as an energy source
Table 5 Summary of the in vivo experiments
Group Number of mice
inoculated
Tumors Died
early
Tissue
harvest
468-WT 13 13 0 13
468-shSCR 13 13 0 13
468-shCDH1-B 13 13 0 13
468-shCDH1-D 13 13 01 12
468-pcDNA3 12 09 0 12
468-CDH1 12 12 0 12
sh Short hairpin, SCR Scrambled, WT Wild type
The E-cadherin-modified MDA-MB-468 cell lines were orthotopically inoculated
to the right mammary fat pads of severe combined immunodeficiency mice
(n = 12–13 per group). The groups inoculated with wild-type MDA-MB-468
(468-WT), 468-shSCR, 468-shCDH1-B, 468-shCDH1-D, and 468-CDH1 developed
tumors in all mice. In the 468-pcDNA3 group, 9 of 12 mice developed tumors.
One mouse from the 468-shCDH1-D group died before harvest as a result of
non-tumor-related causes
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[74]. To determine whether the 468-shCDH1-B tumors
did not express HIF-1α because of E-cadherin knock-
down or whether the cells simply did not experience
HPX in vivo, we cultured these cells in hypoxic condi-
tions in vitro and assessed HIF-1α expression. As shown
in Fig. 6c, 468-shCDH1-B and 468-shCDH1-D cells
showed induction of the HIF-1α gene-regulated gene
carbonic anhydrase 9 (CAIX) under HPX to a level simi-
lar to that of the SCR control, indicating that the hyp-
oxic response was still intact, at least in vitro.
EMT in xenograft tumors from E-cadherin-manipulated
MDA-MB-468 cells
As seen in WT tumors (Fig 1a), in all tumors except
468-shCDH1-B and to some extent 468-shCDH1-D,
vimentin-positive cells were observed at the invasion
front along the tumor-stroma border and also at the
tumor-necrosis border, indicative of EMP (Fig. 7a). Gen-
erally, as seen in the MDA-MB-468 WT tumors, the
cells at the invasive front of the various xenograft tu-
mors appeared to be arranged in thin rows in “Indian
file” formation, interspersed among the stromal connect-
ive tissue. In addition, some individual cells were sepa-
rated from the main tumor mass and located at the
extreme periphery of the invasive front (indicated by
blue arrow in 468-WT in vivo vimentin-E-cadherin low-
power image in Fig. 7a). The majority of the cells at the
invasive front expressed vimentin, indicating EMT in
this area, whereas some of the cells coexpressed both
vimentin and E-cadherin, highlighting the existence of a
a (i)
b (i)
(ii)
(ii)
Fig. 5 a Rate of xenograft tumor growth. Individual tumor volumes from each mouse from each group were averaged and plotted against the
number days postinoculation. Statistical significance was determined by two-way analysis of variance (ANOVA) with Sidak’s posttest; ** p < 0.001,
* p < 0.05. (i) E-cadherin overexpression group. (ii) E-cadherin knockdown group. b The tumor/necrosis ratio. (i) Hematoxylin and eosin staining of
xenograft tumors, low magnification. N Necrotic area. Blood vessels are indicated by red arrowhead. Scale bar = 50 μm. (ii) Percentage of viable
tumor tissue/remaining tumor mass. Statistical significance was determined by one-way ANOVA; *** p < 0.001
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hybrid cell state able to respond quickly to external
stimuli [75]. However, none of the cells at the invasive
front demonstrated HIF-1α positivity, indicating a lack
of HPX in this region (data not shown, but Fig. 1a is
representative of these results). These observations sup-
port the existence of EMP at the invasive front, which is
not a result of HPX.
In contrast, E-cadherin was expressed strongly in
epithelial cells located in the tumor proper, in be-
tween the vimentin-positive borders, in 468-WT, 468-
shSCR, 468-pcDNA3, and 468-CDH1 tumors (Fig. 7a).
Although the E-cadherin was overexpressed in 468-
CDH1 cells in vitro (mRNA) (Fig. 3s, ii), no visible
difference was seen in the intensity of E-cadherin
staining between 468-CDH1 and the vector control
468-pcDNA3 tumors; however, the ability to distin-
guish the two colors as separate entities (i.e., E-
cadherin and vimentin) in the 468-CDH1 tumors did
appear somewhat compromised (Fig. 7b). Vimentin
induction in these tumors was not blocked, however,
which was unexpected. A few areas of E-cadherin-
expressing cells were seen in both 468-shCDH1-B
a
c
b
Fig. 6 a Immunohistochemistry for CD31 (left panel), with smaller vessels indicated by red arrowheads and larger vessels indicated by green
arrowheads. b Plot of the average number of CD31-stained blood vessels in five random microscopic fields (original magnification × 200) per tumor.
Statistical significance was assessed by one-way analysis of variance (no difference across groups). c. Quantitative polymerase chain reaction data for
hypoxic indicator gene carbonic anhydrase 9 (CAIX) (n = 3). Error bars represent SE. ΔCT Cycle threshold change, SCR Scrambled, WT Wild type
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and 468-shCDH1-D tumors; however, this appeared
very weak compared with the 468-shSCR staining.
Conversely, vimentin-expressing cells in the 468-
CDH1 tumors were prominent at the tumor-stroma
border, with one vimentin-positive cell being visible at
high power (468-CDH1 high-power image shown in
Fig. 7a, green arrow).
E-cadherin-knockdown cells displayed EMT in vivo
In 468-shCDH1-B and 468-shCDH1-D tumors, the major-
ity of the cells showed strong vimentin staining, indicating
widespread EMT in these tumors (Fig. 7a). This is in con-
trast to the in vitro findings with these cells, where vimen-
tin mRNA was not induced constitutively after E-cadherin
reduction (Fig. 3c, comparing no EGF controls). To
a
c b
Fig. 7 a Epithelial-mesenchymal plasticity status in vivo as xenografts in mice. E-cadherin was assessed by double-immunohistochemistry (IHC) of
E-cadherin (brown) and vimentin (red). Vimentin-positive cells at tumor-stroma interface are indicated by blue arrowheads, and at tumor-necrosis
border they are indicated by red arrowheads. Red-channel images are shown for vimentin IHC clarity. All scale bars = 50 μm. b Enlargement of
468-pcDNA3 and 468-CDH1 tumors showing differences in vimentin-E-cadherin staining. c Quantitative polymerase chain reaction expression of
the same modified cells grown in 2D versus 3D. ΔCT Cycle threshold change, SCR Scrambled, WT Wild type
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determine whether global induction of vimentin in these
E-cadherin-knockdown tumors was due to the 3D state in
vivo, we cultured each of the control and sh-CDH1 cells in
3D Matrigel compared with 2D monolayer cultures. We
confirmed the lack of vimentin mRNA induction seen in
2D (Fig. 3) and found no further stimulation when the cells
were cultured in the 3D environment (Fig. 7c).
The increased in vivo expression of vimentin protein by
IHC in 468-shCDH1-B tumors corresponded with upreg-
ulated expression of vimentin in matching xenograft
tumor RNA (Fig. 8). SNA1 was also significantly upregu-
lated in these tumors. This correlated with a significant
downregulation of the estrogen receptor alpha (ESR1), a
known Snail1 transcriptional target for repression [76].
SNA1 was variably expressed in a pattern similar to that
observed for vimentin, where it was induced in vivo in the
E-cad-knockdown tumors but not in vitro, and ESR1
followed suit (Fig. 8). Inhibin, beta A (INHBA) and
LAMC2 were also upregulated in the E-cadherin-
knockdown 468 lines grown in vivo, whereas this was not
seen when the cells were plated in 2D culture, and FOSL1
was more highly expressed in vivo (Fig. 8).
E-cadherin was expressed in tumor emboli located within
local vasculature, regardless of E-cadherin manipulation
status
All WT, 468-SCR, and 468-pcDNA3 groups displayed
features similar to those shown in Fig. 2. E-cadherin was
Fig. 8 Quantitative polymerase chain reaction gene expression analyses of 468-shCDH cell xenografts (in vivo) versus plated in 2D culture (in vitro).
Results shown are average expression of RNA extracted from three tumors or from three biological replicates of cells plated in 2D. Error bars represent
SE. Significance was set at p < 0.05 and is indicated by asterisk and determined by Student’s paired t test (compared with 468-shSCR control). ΔCT Cycle
threshold change, SCR Scrambled, WT Wild type, ESR1 Estrogen receptor alpha, INHBA Inhibin, beta A, SNAI1 Snail family transcriptional repressor 1
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homogeneously expressed in all groups, except for the
468-shCDH1-B and 468-shCDH1-D tumors, where it
was expressed at a less intense level than the control
and in a heterogeneous pattern (Fig. 9a, lower right
panel). Although local lymphovascular invasion (LVI)
was seen across all the tumor groups, no clear associ-
ation was detected between LVI and the E-cadherin sta-
tus of the primary xenograft (Table 6). Generally, LVI
was more apparent in larger tumors, except for the 468-
shCDH1-B and 468-shCDH1-D groups, where the LVI
was clearly seen even with smaller primary tumors
(Fig. 9c).
a
cb
Fig. 9 a. Dual immunohistochemistry staining (red = vimentin, brown = E-cadherin) of CDH1-modified cell line xenografts. Original magnification ×
40 and × 400. b Closer inspection of 468-shCDH1-B (top, hematoxylin and eosin [H&E] staining; bottom, dual E-cadherin and vimentin staining)
with higher-magnification inset. Scale bar = 50 μm. c Two types of extratumoral local lymphovascular invasion observed in tumors. Invaded cells
presented as tumor emboli composed of well-cohesive tumor cells (top panel, left), and more rarely seen invaded cells remained as scattered
individual cells (top row, right). 468-shCDH1-B tumor emboli were smaller than the rest and composed of loosely adhered cells (middle row).
Tumor cells were also observed within intratumoral blood vessels of 468-shCDH1-B tumors (bottom row). WT Wild type
Table 6 Local lymphovascular invasion
Group Number of mice
inoculated
With
tumors
With local
invasion
Percentage
of invasion
468-shSCR 13 13 8 61.5
468-shCDH1-B 13 13 8 61.5
468-shCDH1-D 12 12 11 91.7
468-pcDNA3 12 9 5 41.7
468-CDH1 12 12 11 91.7
Local invasion of the lymphovascular spaces was a common feature in many
tumors across all the groups, and no clear association was detected between
it and the E-cadherin status of the primary tumors
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The majority of tumor emboli seen in vessels were
E-cadherin-positive, indicating their epithelial pheno-
type. Although it is generally accepted that MET oc-
curs to facilitate growth at the secondary site, our
observations suggest that it may occur earlier in the
bloodstream and further support the requirement of
epithelial features, potentially through MET, during
metastatic progression.
The presence of multinuclear tumor giant cells is indi-
cative of the highly aggressive nature of the 468-
shCDH1-B group (Fig. 9b). These features stained posi-
tive for human vimentin, indicating their human origin.
Trend for association of lung metastases with higher
E-cadherin level
Attempts to assess the lung metastasis efficiency of the
different MDA-MB-468 cell populations via experimen-
tal metastasis were unsuccessful because tail vein injec-
tion in SCID mice did not result in any lung metastases
in our hands. However, our experiments were compro-
mised by the small number of lung metastases arising
from the orthotopic primary xenografts across all groups
(Table 4). The incidence of lung metastases, expressed
as a percentage of mice in each group with lung metas-
tases, appeared markedly lower in mice carrying 468-
shCDH1-B or 468-shCDH1-D xenografts than with the
468-SCR, suggesting that E-cadherin knockdown ad-
versely affected the establishment of secondary colonies;
however, this trend observed among the groups was not
significant. This assumption was reinforced by the obser-
vation that the percentage of mice with lung metastases
was slightly higher in the E-cadherin-overexpressing
468-CDH1 group than in the vector control (Table 4).
Although the tumors grew at different rates, the mice
were harvested as close to the same size as possible
(Additional file 2: Figure S2b).
Correlation of CDH1 protein expression with distant
metastasis-free survival in individuals with breast cancer
To determine whether E-cadherin expression predicted
distant metastasis formation, an analysis of public breast
cancer databases that had outcome data was performed
[77, 78]. Patients’ breast tumors were separated accord-
ing to PAM50 intrinsic subtypes (basal, HER2-positive,
luminal A, luminal B, or normal), and the mean centered
CDH1 expression was examined (Fig. 10a, i). In patients
with tumors of the luminal B subtype, E-cadherin ex-
pression was expressed the highest (p > 0.001 by one-
way ANOVA for luminal B versus basal). Of the various
tumor subtypes, a greater percentage of samples with
distant metastases was observed when they were of the
luminal B subtype, and subsequently this tumor type
was more likely to present as metastasis within 15 years
(Fig. 10a, ii and iii, respectively) (p < 0.0001). When
these same data were plotted as the presence or absence
of metastasis, CDH1 expression was a determining factor
(Fig. 10b, i) (p = 0.0037). This was consistent with ana-
lysis of The Cancer Genome Atlas breast cancer dataset
[77] (Fig. 10b, ii) (p = 0.0085), in which tumors were sep-
arated on the TNM staging scale of M0 being no distant
metastasis and M1 indicating tumors that metastasized
to distant organs (i.e., beyond the regional LNs).
Discussion
As previously reported [66], we have shown that the
MDA-MB-468 human breast cancer cell line displays
significant EMP in vivo, dynamically switching on a
mesenchymal phenotype in the primary tumor either at
the periphery or in response to HPX (EMT) but exhibit-
ing a predominantly epithelial phenotype in the xeno-
graft center and at the secondary sites in local LNs and
the lung. Our in vivo study suggests that in this model,
E-cadherin is a major phenotypic driver for metastatic
colonization and is lost in EMT sites of the primary
tumor, and this was supported by the poorer survival
seen in grade III breast cancers expressing high levels of
E-cadherin mRNA. The sustained and exaggerated EMT
seen after E-cadherin suppression by shRNA in vivo,
however, was not readily seen in vitro, suggesting that
other factors in the tumor microenvironment are neces-
sary for the full EMT program. Further to this, we have
identified that E-cadherin promotes primary tumor
growth but may also be important for the formation of
lung metastases, thus disputing the previously held no-
tion of E-cadherin as a tumor suppressor [79].
Evidence challenging the tumor suppressor status of
E-cadherin
Evidence for E-cadherin’s role as a tumor suppressor has
accumulated, with downregulation of CDH1 being linked
with epithelial tumor progression [79, 80], although its
reexpression in tumors is reported to promote metasta-
sis in later stages of tumor progression (reviewed in
[14]). Indeed, inactivating mutations of the CDH1 gene
in gastric and lobular breast cancers have defined E-
cadherin as a tumor suppressor for these cancer types
(reviewed in [81]). However, E-cadherin has an unex-
pected proneoplastic effect in ovarian cancer [82]. CDH1
is upregulated in proliferating ovarian cancers, in which
its suppression inhibits their proliferation [83, 84] and
its proliferation-promoting effects in this context have
been shown to occur via mitogen-activated protein kin-
ase kinase/extracellular signal-regulated kinase pathway
activation [85]. Perhaps consistent with this, breast can-
cers expressing higher levels of the epithelium-
promoting miR-200 family that represses the CDH1-sup-
pressing EMP drivers ZEB1 and ZEB2 have poorer out-
comes; however, this appeared to be due to mechanisms
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additional to E-cadherin regulation [86]. Chu et al. [74],
who also showed a reduced proliferative state after E-
cadherin knockdown in the human breast cancer cell
lines MARY-X and SUM149, found that higher levels of
E-cadherin in basal breast cancers were associated with
poorer outcome, consistent with our observations in lu-
minal B tumors (Fig. 10). CDH1 and proliferative
markers also correlated in a study of endometrial cancer
[87] and have been associated with malignant and meta-
static potential in bladder and prostate cancer cell lines
[88]. We have also shown in the PMC42 human breast
cancer model system that cellular proliferation was asso-
ciated with an epithelial phenotype because the stable
knockdown of ZEB1 in PMC42-ET cells resulted in
CDH1 reexpression along with an increased proliferative
rate [38].
E-cadherin-knockdown cells grew more slowly in vitro
and in vivo
In the present study, we have shown that E-cadherin
greatly enabled the proliferation of MDA-MB-468 cells
in vitro. These in vitro effects were recapitulated in the
a (i)
b (i) (ii)
(ii)
(iii)
Fig. 10 E-cadherin expression correlates with poor clinical outcome for patients with breast cancer. a Analysis of clinical data of breast cancers
separated according to PAM50 intrinsic subtype from a publicly available microarray study [78]. (i) CDH1 expression. **** p > 0.001, ** p < 0.01, by
one-way analysis of variance versus basal. (ii) Percentage of patients positive or negative for distant metastasis. (iii) Kaplan-Meier curve depicting
the correlation between breast cancer subtype and distant metastasis-free survival. p Value was determined by the log-rank (Mantel-Cox) statistical test.
b Breast cancers that did or did not metastasize to distant sites were analyzed with respect to E-cadherin expression. (i) Data from Yau et al. [78], the
same data source used for figures shown in (a) and (ii) [77]. p Values were determined by Welch’s t test
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in vivo setting with dramatically reduced xenograft
growth after E-cadherin suppression, with one minor ex-
ception: growth of the 468-shCDH1-D cells. These cells
plated in vitro exhibited a noticeable reduction in prolif-
eration rate only when plated sparsely (Fig. 4c, i). It is
reasonable to assume that the growth environment of
the tumors formed from these cells would not have been
sparse; yet, as shown in Fig. 5a(ii), the 468-shCDH1-D
tumors grew significantly slower than the control, indi-
cating additional tumor microenvironmental factors at
play.
Consistent with our overall findings that E-cadherin
enabled cellular proliferation, a subline of the DU145
human prostate cancer cell line with strong E-cadherin
expression formed xenograft tumors, whereas a subline
of cells with weak E-cadherin expression did not form
tumors at all [89]. Moreover, Celià-Terrassa et al.
showed that the proliferative, malignant, and metastatic
competence of both prostate (PC-3) and bladder (T24-
TSU) cell lines required E-cadherin expression, which
also coincided with expression of pluripotency genes,
and that manipulation of CDH1 or pluripotency genes
reciprocally affected each other [88]. A reduction in
tumor growth has also been seen in MFP tumors of E-
cadherin-knockdown SUM149 and MARY-X human
breast cancer cells, in 4 T1 mouse mammary carcinoma
cells, and in SUM149 cells engineered to overexpress
ZEB1, all of which demonstrated dramatic growth re-
tardation compared with their respective controls [74].
HIF-1α and E-cadherin mechanistic effects on proliferation
Gene expression analysis of the xenograft tumors from
Chu et al. [74] revealed that E-cadherin knockdown
caused a loss of HPX response genes, including HIF-1α,
and that normal growth rate was restored in E-cadherin-
knockdown SUM149 xenografts by overexpressing HIF-
1α. In this particular study [74], it was deduced that the
E-cadherin shRNA cell lines had a diminished ability to
respond to hypoxic stress, and examination of the cells
in vitro revealed a reduced capacity for glycolysis, which
affected energy availability and growth potential. In the
present study, we found that HIF-1α expression was no-
ticeably absent in 468-shCDH1-B tumors (which exhib-
ited the best E-cadherin knockdown), whereas HIF-1α
was strongly expressed at the necrotic perimeter in tu-
mors from other cell groups (Fig. 6a, right panel). Given
that 468-shCDH1-B tumors also grew the slowest in our
studies, we considered the possibility that growth of the
468-shCDH1-B tumors was hampered by the inability of
these cells to access energy by glycolysis and thus to sur-
vive in the hypoxic environment, as shown in E-
cadherin knockdown in SUM149 cells [74]. We found,
however, that the 468-shCDH1-B cells were not im-
paired in their ability to upregulate the HPX-inducible
gene CAIX in hypoxic conditions simulated in vitro
(Fig. 6c). It is probable that these tumors did not express
HIF-1α because they did not experience HPX, most
likely attributable to their better-developed blood vascu-
lature (Fig. 6a, left panel) afforded by slower tumor
growth.
Snail1 repressive effects on proliferation
We demonstrated in our previous study that Snail1 and
Snail2 were expressed in vimentin-positive zones within
the MDA-MB-468 xenografts [66]. These act directly on
the cell cycle to downregulate cellular proliferation [90–
92]. The 468-shCDH1-B tumors that were slowest-
growing also homogeneously expressed vimentin. These
tumors also showed upregulated SNA1 (Fig. 8), which
may have led to the observed slowed growth of these tu-
mors (Fig. 5a, ii; Additional file 2: Figure S2a). Loss of E-
cadherin at the cell membrane may have fueled SNA1
transcription via freed β-catenin acting in the nucleus
[93]. ESR1 was downregulated in the 468-shCDH1-B tu-
mors, a transcriptional target of SNA1 in EMT [76]. This
provides support for the hypothesis that, in addition to
upregulated SNA1 mRNA in the 468-shCDH1-B tumors,
this resulted in upregulated Snail1 protein, which was
transcriptionally active.
E-cadherin loss does not always result in reduced cellular
proliferation
Although we have reviewed several lines of evidence to
show that E-cadherin expression may provide a certain
growth advantage in vivo, both in the onset of primary
tumors and in their metastases, contradictory data sug-
gest that loss of E-cadherin in some cell contexts does
not reduce proliferation, and this is an important caveat.
Indeed, proliferation is not always downregulated in
EMP [94], and the EMP regulator and CDH1 suppressor
ZEB1 plays a pro-proliferative role in certain contexts
[95, 96]. The lack of EMP in lobular breast cancer, which
is defined by loss of E-cadherin, suggests that lobular
carcinoma cells have constraints that avoid any manifest-
ation of EMP [67], and their lack of E-cadherin does not
appear to compromise their ability to grow, perhaps due
to some genomic override. In mammary systems, the re-
lationship between EMP and stemness was accompanied
by reduced proliferation in some studies [9, 43]; how-
ever, EMP induced by ectopic expression of FOXC2 in
EpRas cells did not affect either their proliferation rate
in vitro or the growth kinetics of the resulting primary
tumors in nude mice [29]. Ongoing stemness after MET
has been suggested in studies examining PRRX1, a gene
mediating EMT in migrating and invading cancer cells;
downregulation of PRRX1 enables epithelial reversion,
maintenance of stemness, and metastasis formation [50].
It is important to appreciate that the positive
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relationship between E-cadherin and proliferation de-
scribed here, and as seen in several other systems, is not
universal; however, the explanation for this remains
unclear.
E-cadherin-knockdown cells displayed a pronounced EMT
within the tumor microenvironment
The extent of in vivo vimentin expression across the
various tumor groups strongly correlated with E-
cadherin status (Fig. 7a). This was best observed in 468-
shCDH1-B tumors, which displayed the best E-cadherin
knockdown (Fig. 3B), and also displayed the highest and
most homogeneous expression of vimentin protein
(Fig. 7a) and mRNA (Fig. 8). Upregulated VIM expres-
sion was not observed in the 468-shCDH1-B or 468-
shCDH1-D cells when plated in 2D or 3D (mRNA;
Fig. 3c, ii, and Figs. 7c and Fig. 8, respectively), nor did
the altered SNA1, ESR1, INHBA, and LAMC2 expression
(from control) observed in tumors (Fig. 8) correlate in in
vitro culture of the corresponding cells (Fig. 8). Induc-
tion of EMT by EGF did occur more easily (Fig. 3C),
however. These results are similar to the findings of
Chen et al., who showed that stable loss of E-cadherin in
MCF10A cells did not drive EMT [97] and that loss of
E-cadherin was not necessary or sufficient to induce
EMT in cultured breast cells [98], as opposed to studies
where E-cadherin loss did lead to EMT in vitro [71, 99].
It is likely that the in vivo EMT in the present study was
influenced by murine stromal factors or biophysical in-
fluences. These stromal factors may also have induced
an EMT at the tumor-stroma border in 468-WT tumors
(Fig. 1a). One plausible host stromal candidate could in-
clude mast cell-derived interleukin-6, which we have
previously implicated in a positive feedback cycle be-
tween tumor cells and host myofibroblasts in MDA-MB-
468 xenografts [100], although other soluble factors,
microRNAs, and exosomes have been found to be re-
leased from tumor-activated stromal cells to promote
EMT (reviewed in [101]). It is also possible that the dur-
ation of culture of these cells in the mouse (up to
154 weeks) led to different outcomes than seen in the
relatively shorter time frames used in vitro.
E-cadherin expression in metastases: importance of MET
in secondary tumor formation
WT MDA-MB-468 tumor cells that were found in the
lung as micrometastases expressed E-cadherin, whereas
no vimentin-positive cells were observed (Fig. 2b). Cells
from the same primary tumor that invaded into the axil-
lary LNs also demonstrated E-cadherin expression, with
the E-cadherin signal in these cells even stronger than
that of the primary tumor (Fig. 2c). E-cadherin expres-
sion may be advantageous for the formation of these
lung metastases because we observed a trend toward a
higher number of micrometastases in this organ in the
mice carrying xenografts with forced E-cadherin (468-
CDH1) than in their controls, as well as a reduced num-
ber when E-cadherin was knocked down despite the
considerably longer tumor exposure time (Table 4). The
sh-CDH1 xenografts grew slower, so the potential to
seed metastases may have been reduced, and the lung
metastases may have also grown slower. Kowalski et al.
[102] reported results showing distant metastases ex-
pressing an E-cadherin signal equal to or stronger than
that of the respective primary tumors from which they
originated. They saw all metastatic tumors of invasive
ductal carcinoma reexpressing E-cadherin, regardless of
the E-cadherin status of the primary tumors. In other
studies, Saha et al. [103] showed reexpression of E-
cadherin in bone metastases that originated from E-
cadherin-negative, poorly differentiated primary breast
carcinoma, and Chao et al. [46] reported the reexpres-
sion of E-cadherin at distant metastases arising from E-
cadherin-low or E-cadherin-negative primary tumors.
They reported strong E-cadherin expression in more
than 50% of liver, brain, and lung metastasis originating
from infiltrating ductal carcinoma of the breast, as well
as in lung metastases from E-cadherin-negative MDA-
MB-231 primary xenografts. They suggested that the
reexpression of E-cadherin in metastases was influenced
by the microenvironment of the metastatic site. To
investigate their hypothesis, they demonstrated that the
E-cadherin-negative MDA-MB-231 cells expressed E-
cadherin when cocultured with hepatocytes. Similarly,
activation of fibroblasts at the metastatic niche is medi-
ated by AXL, expressed by mesenchymal circulating can-
cer cells homing to the niche, which has been shown to
be necessary for metastatic colonization and MET [104].
Gao et al. showed that bone marrow-derived myeloid
precursor cells produced versican that could neutralize
transforming growth factor β1 in the lung, promoting
MET and metastatic competence in MDA-MB-231 cells
[105]. MET may also occur in circulating tumor cells
(CTCs) shed from the primary tumor, as has been shown
in small cell lung cancer, where it has been postulated
that the large CTC clusters that form may do so in re-
sponse to the selection pressure of first-line chemother-
apy [106]. Assessment of CTCs in a separate study of
MDA-MB-468 xenografts showed significantly increased
expression of both mesenchymal (SNAIL1, Notch homo-
log 1, translocation-associated [Drosophila] [NOTCH1],
SERPINE1, insulin-like growth factor 1 receptor, Ras-
related protein R-Ras, neurophilin 1, INHBA), and epi-
thelial (B-lymphocyte antigen CD20, CDH1, bone mor-
phogenetic protein 7, claudin 3) markers (Tachtsidis, Li
et al., unpublished data). VIM was increased, but not sig-
nificantly. These findings, combined with those of the
present study, support the importance of epithelial
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phenotype/MET tumor cell survival in the bloodstream
and in the formation of secondary tumors and a central
role for E-cadherin in this mechanism [107, 108].
Features of aggressiveness in 468-shCDH1-B tumors
Consistent with their more invasive status as established
by the Transwell migration assays (Fig. 4a, ii), 468-
shCDH1-B displayed classical “high-grade” tumor ag-
gressiveness features such as multinucleated giant cells
(Fig. 9b) and an Indian file histology characteristic of
lobular breast cancers, which are defined by a lack of E-
cadherin. The presence of such morphologies in invasive
breast carcinoma has been reported, although the origin
of those cells has been a subject of controversy [109–
111]. Factor et al. suggested that giant cells are histio-
cytic descendants [109], whereas Kobayashi et al. pro-
posed that they originated from the tumor cells through
abnormal cell division [110]. Another study suggested
that tumor giant cells are generated through the fusion
of mononuclear stromal cells other than histiocytes
[111]. Given that these cells expressed human vimentin,
it appeared that these giant cells were of tumor origin.
MDA-MB-468-shCDH1-B tumors grew more slowly
than controls (Fig. 5a, ii), and thus, combined with the
expression of these aggressive phenotypic features, these
findings challenge the generally accepted view of “the
higher the grade, the more aggressive and fast-growing
the cancer.”
E-cadherin expression determines distant metastasis
formation
In our study, we have shown that the E-cadherin-
knockdown cell lines displayed a trend toward fewer
lung metastases (Table 4), indicating that E-cadherin is
important for the formation of these secondary tumors.
A previous study looking at E-cadherin expression in
tumors of all types and patient survival found that E-
cadherin did not have predictive value [86], whereas
another study showed that E-cadherin expression (in
basal tumors specifically) was associated with a poor
prognosis [74]. The clinical data shown in Fig. 10 are
consistent with this latter finding and demonstrate that
E-cadherin expression is a feature of tumors that
metastasize to distant sites, concordant with the results
of another study in which it was shown that luminal B
breast cancers are associated with a poorer prognosis
[112]. In this particular study, they showed that this
breast tumor subtype was also more proliferative, dis-
playing a higher Ki-67 score. This is consistent with
our finding that E-cadherin promotes a proliferative
phenotype, as shown in Figs. 4 and 5. Taken together,
E-cadherin expression in breast cancer has significant
implications for patient outcome.
Conclusions
We have shown that E-cadherin expression sustains pro-
liferation in MDA-MB-468 breast cancer cells in culture
and within the growing tumor at both orthotopic and
metastatic sites in the SCID mouse. We have also dem-
onstrated that EMP is influenced by the tumor micro-
environment and is stimulated by HPX and stromal
interactions. We have shown that predominantly epithe-
lial features are seen in tumor-associated LVI, proximal
vascular emboli, and local LNs, as well as in lung metas-
tases, and these are consistent with our independent
studies of CTCs in this model. Our review of the clinical
data with respect to E-cadherin expression in breast tu-
mors support that E-cadherin expression positively pre-
dicts the formation of metastases. These findings
indicate the requirement of a reappraisal of the precise
role of E-cadherin in predicting primary tumor progres-
sion and metastatic risk.
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